



# Connected Home Hemodialysis Machine Use and Transition to In-Center Hemodialysis for Home Hemodialysis Patients

Miranda Hurtado, MPH;<sup>1</sup> Meredith Zywno, MSPH;<sup>1</sup> Eric D. Weinhandl, PhD, MS;<sup>2,3</sup> Mihran V. Naljayan, MD, MHA<sup>1,4</sup>

<sup>1</sup>DaVita Inc, Denver, CO; <sup>2</sup>DaVita Clinical Research, Minneapolis, MN; <sup>3</sup>University of Minnesota, Minneapolis, MN; <sup>4</sup>LSU School of Medicine, New Orleans, LA

## Introduction

- Although home hemodialysis has been growing rapidly in the United States, ongoing expansion is constrained by relatively high rates of transition to in-center hemodialysis (ICHD) during the first year of the therapy.
- The use of internet-connected devices that transmit treatment data to the healthcare provider in real time may help in identifying areas where patients need additional support – potentially aiding in preventing transition to ICHD.

## Objective

We aimed to assess whether the use of an internet-connected home hemodialysis machine (CC), which employs a detached tablet and relays treatment data to the dialysis provider, was associated with a decreased rate of transitioning to ICHD from home hemodialysis (HHD).

## Methods


- The study population included all HHD patients who began treatment in a large dialysis provider organization between July 2021 and December 2022 and initiated use of a CC [NxStage System One with Nx2me Connected Health, Fresenius Medical Care] within 30 days of first documented treatment.
- Patient data were obtained from electronic medical records and initiation of CC was ascertained from electronic treatment records.
- Patients were followed from 30 days after HHD initiation until the earliest of transition to ICHD, death, kidney transplant, or end of study follow-up.
- Kaplan-Meier estimation and Cox regression were used to compare technique survival in CC and non-CC patients at 90 days and 360 days; death and transplantation were classified as censoring events.
- Given the limited sample size of patients not using a CC, matching techniques were not able to be employed. Baseline patient characteristics were collected to ensure both the study and control group were comparable.

## Results

Table 1: Baseline Patient Characteristics

	Non-CC Patients (n = 637)	CC Patients (n = 930)
Female	258 (40.5%)	352 (37.8%)
Dialysis Vintage (yrs.)	2.40 [0.0054, 34.8]	1.68 [0.0027, 29.3]
Age (yrs.)	60.0 [19.0, 97.0]	53.0 [15.0, 99.0]
Race/Ethnicity		
American Indian or Alaskan Native	2 (0.3%)	3 (0.3%)
Asian	19 (3.0%)	31 (3.3%)
Black	214 (33.6%)	252 (27.1%)
Hispanic	58 (9.1%)	104 (11.2%)
Middle Eastern or North African	3 (0.5%)	6 (0.6%)
Native Hawaiian or Other Pacific Islander	7 (1.1%)	12 (1.3%)
Other	26 (4.1%)	33 (3.5%)
White	308 (48.4%)	489 (52.6%)

Figure 1: Kaplan-Meier Curve for Home Patient Retention Over Time by CC Use



## Results and Conclusions

- The study cohort included 1,563 patients, among whom 930 (60%) used a CC. Mean age among patients was 55.8 years, and 39% of patients were female.
- In the HHD patient population, CC and non-CC patients had no significant difference in risk of transitioning to ICHD (hazard ratio: 1.00, 95% confidence interval: 0.82, 1.21).
- However, when follow-up was limited to the first 180 days, CC patients experienced a 22% lower rate of transition to ICHD, compared to non-CC patients (hazard ratio: 0.78, 95% confidence interval: 0.61, 1.00).
- The use of a connected cyclor was not associated with a differential risk of transition to ICHD from HHD in our study population, although there was evidence of potential benefit during the first 6 months of modality.
- More study is needed to determine whether this technology could positively impact home modality retention.

## References

1. Schreiber, M. J., Chatoth, D. K., & Salenger, P. (2021). Challenges and Opportunities in Expanding Home Hemodialysis for 2025. *Advances in chronic kidney disease*, 28(2), 129–135. <https://doi.org/10.1053/j.ackd.2021.06.009>

## Acknowledgments

We would like to express our sincere gratitude to teammates at DaVita clinics for their daily commitment to patient care and for supporting the extensive data collection that forms the foundation of our work.

Correspondence: [Miranda.Hurtado@davita.com](mailto:Miranda.Hurtado@davita.com)

American Society of Nephrology Kidney Week, October 23-27, 2024, San Diego, CA